AU2013312358B2 - Treating hearing loss - Google Patents

Treating hearing loss Download PDF

Info

Publication number
AU2013312358B2
AU2013312358B2 AU2013312358A AU2013312358A AU2013312358B2 AU 2013312358 B2 AU2013312358 B2 AU 2013312358B2 AU 2013312358 A AU2013312358 A AU 2013312358A AU 2013312358 A AU2013312358 A AU 2013312358A AU 2013312358 B2 AU2013312358 B2 AU 2013312358B2
Authority
AU
Australia
Prior art keywords
khz
pct
rule
substitute sheet
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013312358A
Other languages
English (en)
Other versions
AU2013312358A1 (en
Inventor
Albert Edge
Masato Fujioka
Kunio MIZUTARI
Hideyuki Okano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Publication of AU2013312358A1 publication Critical patent/AU2013312358A1/en
Application granted granted Critical
Publication of AU2013312358B2 publication Critical patent/AU2013312358B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2013312358A 2012-09-07 2013-09-06 Treating hearing loss Active AU2013312358B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698475P 2012-09-07 2012-09-07
US61/698,475 2012-09-07
PCT/US2013/058446 WO2014039781A1 (en) 2012-09-07 2013-09-06 Treating hearing loss

Publications (2)

Publication Number Publication Date
AU2013312358A1 AU2013312358A1 (en) 2015-03-19
AU2013312358B2 true AU2013312358B2 (en) 2018-08-09

Family

ID=50237627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013312358A Active AU2013312358B2 (en) 2012-09-07 2013-09-06 Treating hearing loss

Country Status (7)

Country Link
US (3) US20150209367A1 (enExample)
EP (2) EP2892506B1 (enExample)
JP (4) JP2015527398A (enExample)
AU (1) AU2013312358B2 (enExample)
CA (1) CA2883896C (enExample)
HK (1) HK1211875A1 (enExample)
WO (1) WO2014039781A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2014039781A1 (en) * 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
EP3368553B1 (en) * 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
KR102130458B1 (ko) 2015-10-30 2020-07-08 파이프라인 테라퓨틱스, 아이엔씨. 디벤조 아제핀 화합물 및 귀 질환과 귀 장애 치료에서의 그의 용도
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017132530A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
AU2017376109A1 (en) * 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
US20220192984A1 (en) 2018-10-02 2022-06-23 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
KR20220007050A (ko) 2019-04-08 2022-01-18 프리퀀시 테라퓨틱스, 인크. 난청을 치료하기 위한 chir99021과 발프로산의 조합
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124568A1 (en) * 2003-11-13 2009-05-14 Massachusetts Eye & Ear Infirmary Use of stem cells to generate inner ear cells
US20090297533A1 (en) * 2008-05-23 2009-12-03 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2010060088A2 (en) * 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US20110033480A1 (en) * 2006-04-11 2011-02-10 Partha Sarkar Methods and compositions involving nucleotide repeat disorders

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
USD309535S (en) 1987-03-30 1990-07-31 Chromcraft Furniture Corp. Chair
USD360535S (en) 1994-02-14 1995-07-25 Staffan Sjoberg Combined beach chair and beach mattress
PT951466E (pt) 1996-12-23 2009-04-09 Lilly Co Eli Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683048B1 (en) 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
EP1254108A1 (en) 2000-01-24 2002-11-06 MERCK SHARP & DOHME LTD. Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
ES2275657T3 (es) 2000-03-20 2007-06-16 MERCK SHARP & DOHME LTD. Derivados de bicicloalquilo puenteados sulfonamido sustituidos.
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
USD447031S1 (en) 2000-04-20 2001-08-28 Wang Keaun Oh Hand carry air tacker
AU2001288219C1 (en) 2000-07-11 2009-12-03 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
WO2002036555A1 (en) 2000-11-02 2002-05-10 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US6483732B2 (en) 2000-12-13 2002-11-19 Koninklijke Philips Electronics N.V. Relational content addressable memory
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
AU2004221881A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
CL2004000647A1 (es) 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
WO2005010524A1 (en) 2003-06-04 2005-02-03 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
AU2004268647B2 (en) 2003-08-28 2010-07-01 Choongwae Pharma Corporation Modulation of beta-catenin/TCF activated transcription
EP1667984B1 (en) 2003-09-24 2011-05-18 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
BRPI0507168A (pt) 2004-01-27 2007-06-26 Nuvelo Inc fator proliferativo gastrointestinal e aplicações do mesmo
WO2005072793A1 (en) 2004-01-29 2005-08-11 The Charles Stark Draper Laboratory, Inc. Implantable drug delivery apparatus
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
JP2006117536A (ja) * 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
WO2007030743A2 (en) 2005-09-08 2007-03-15 Massachusetts Eye & Ear Infirmary Cochlear implants containing biological cells and uses thereof
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
WO2007100895A2 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
US8175269B2 (en) 2006-07-05 2012-05-08 Oracle International Corporation System and method for enterprise security including symmetric key protection
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
KR20140007979A (ko) 2008-01-11 2014-01-20 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
CN101990433B (zh) 2008-02-07 2014-11-05 马萨诸塞眼科耳科诊所 提高Atoh1表达的化合物
KR20160029870A (ko) 2008-04-21 2016-03-15 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
GB2459910B (en) 2008-04-21 2010-03-31 Otonomy Inc Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
CN103417472B (zh) 2008-05-14 2018-01-02 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2010068564A1 (en) 2008-12-11 2010-06-17 Merck Sharp & Dohme Corp. Method for treating alzheimer's disease and related conditions
EP2393776B1 (en) 2009-02-06 2014-05-14 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
CN102686580B (zh) 2009-10-28 2014-09-10 美国辉瑞有限公司 用作酪蛋白激酶抑制剂的咪唑衍生物
CA134865S (en) 2010-02-11 2010-11-10 Hankook Tire Co Ltd Automobile tire
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
CN102947451B (zh) 2010-05-26 2017-09-22 库尔纳公司 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
RU2456356C1 (ru) 2011-04-29 2012-07-20 Борис Сергеевич Кустов Коллоидный раствор наносеребра и способ его получения
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014039781A1 (en) * 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
PT3702443T (pt) 2013-03-14 2022-02-17 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
WO2017132530A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
WO2020112883A1 (en) 2018-11-30 2020-06-04 Massachusetts Eye And Ear Infirmary Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124568A1 (en) * 2003-11-13 2009-05-14 Massachusetts Eye & Ear Infirmary Use of stem cells to generate inner ear cells
US20110033480A1 (en) * 2006-04-11 2011-02-10 Partha Sarkar Methods and compositions involving nucleotide repeat disorders
US20090297533A1 (en) * 2008-05-23 2009-12-03 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2010060088A2 (en) * 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BASI GURIQBAL S. ET AL., "Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.", ALZHEIMER'S RESEARCH & THERAPY, vol. 2, (2010), page 36., URL: http://alzres.co/content/2/6/36 *
HORI RYUSUKE ET AL, "Pharmacological inhibition of Notch signaling in the mature guinea pig cochlea", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, UK, (20071203), vol. 18, no. 18, ISSN 0959-4965, pages 1911 - 1914 *
HUYNH C. ET AL., "The novel gamma secretase inhibitor R04929097 reduces the tumor initiating potential of melanoma.", PLOS ONE, (2011), vol. 6, no. 9, page E25264 *
LIN VINCENT ET AL., "Inhibition of notch activity promotes non-mitotic regeneration of hair cells in the adult mouse utricles.", J NEUROSCI, (2011), vol. 31, no. 43, pages 15329 - 15339 *
MASUDA SHIGEO ET AL., "Dual antitumor mechanisms of notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.", CANCER SCI, (2009), vol. 100, no. 12, pages 2444 - 2450 *
SAMON JEREMY B. ET AL., MOLECULAR CANCER THERAPEUTICS, (20120413), vol. 11, no. 7, pages 1565 - 1575 *
WOLFE MICHAEL S., "y-Secretase Inhibition and Modulation for Alzheimer's Disease.", CURR ALZHEIMER RES., vol. 5, no. 2, (2008), pages 158 - 164, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675939/pdf/nihms- 107283.pdf *

Also Published As

Publication number Publication date
US20210299138A1 (en) 2021-09-30
US20150209367A1 (en) 2015-07-30
JP2022109965A (ja) 2022-07-28
CA2883896A1 (en) 2014-03-13
HK1211875A1 (en) 2016-06-03
US12161647B2 (en) 2024-12-10
JP2015527398A (ja) 2015-09-17
EP3970725A1 (en) 2022-03-23
CA2883896C (en) 2023-03-07
US20180369253A1 (en) 2018-12-27
US10898492B2 (en) 2021-01-26
EP3970725B1 (en) 2025-08-20
EP2892506A4 (en) 2016-04-20
EP2892506A1 (en) 2015-07-15
EP2892506B1 (en) 2021-11-03
JP2019172679A (ja) 2019-10-10
WO2014039781A1 (en) 2014-03-13
JP2021038228A (ja) 2021-03-11
AU2013312358A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
AU2013312358B2 (en) Treating hearing loss
Mizutari et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma
US20220339154A1 (en) Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JP2022171847A (ja) 角膜内皮細胞接着促進剤
US20240245702A1 (en) Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
Li et al. Trabodenoson, an adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice
JP2019507802A (ja) ＧＳＫ３α阻害剤を用いる、幹細胞の制御された増殖／内耳有毛細胞の発生のための方法
Zhang et al. Dynamic expression of Lgr6 in the developing and mature mouse cochlea
Chen et al. Transplantation of human limbus–derived mesenchymal stromal cells via occipital approach improves hearing in animal auditory neuropathy
EP3921410A1 (en) Compositions and methods for generating hair cells by inhibiting epigenetic targets
CA3109647A1 (en) Compositions and methods for generating hair cells by upregulating jag-1
US20240382461A1 (en) Pharmaceutical composition and method for prevention and treatment of hearing loss
Kaplan et al. Effects of middle ear application of Cipro HC otic suspension in an animal model.
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction
Henderson R-phenylisopropyladenosine attenuates noise-induced hearing loss in the
Tan Non-viral gene delivery and bone marrow cells in inner ear repair
Pandit Xenotransplantation of adult human olfactory stem cells into mice with early-onset sensorineural hearing loss

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)